How to Set Up a Manufacturing Plant for Hemodialysis Dialysate Concentrates and Dialysis Cleaning Chemicals in India

Hemodialysis Dialysate Concentrate Manufacturing Plant in India

Each day, about 600 Indians are informed that their kidneys are not working. Most will only live long enough if they get dialysis three times a week – forever. In each session, 120–150 litres of dialysate concentrate, a very specific chemical solution that removes blood from the body, are used. If it wasn’t there, the machine would be all metal and plastic.

However, the bad news is that the majority of the dialysis fluid used in India’s rapidly expanding dialysis chains are imported from abroad or produced by just two dozen companies, mostly from Maharashtra and Telangana. In many parts of Jharkhand, Odisha, Eastern Uttar Pradesh and the entire North East patients have to rely on supplies, which come after traversing a distance of 1000-1500 kilometres before reaching the dialysis chair.

The National Health Mission (NHM) estimates that India currently gets around 2.2 lakh new end-stage renal disease (ESRD) patients every year. This number adds up to 3.4 crore additional dialysis treatment each year. The Government’s Pradhan Mantri National Dialysis Programme (PMNDP) has already expanded to 1,704 dialysis centres in 751 districts. All of these centres require concentrate each week. It’s not a niche opportunity this is a structural supply gap in a life-saving industry.

The Supply Gap No One Is Filling Fast Enough

Acute and chronic kidney disease burden in India is not uniform and neither is the supply of dialysate concentrate. IMARC Group’s India Dialysis Equipment Market report indicates that the market is valued at USD 826 million in the year 2021, and is expected to reach USD 1,477 million by 2030, growing at a rate of 6.18% annually. However, there is one weak link in the domestic supply chain that is always a problem: the use of dialysate concentrates, the consumable on which every hemodialysis session depends.

Consider the numbers. Three dialysis sessions per week are required for each patient with regular hemodialysis. The amount of acid concentrate (Part A) needed for each session is about 8–10 litres, while the amount of bicarbonate concentrate (Part B) is 650 ml. Count, say, 7-8 lakh patients undergoing dialysis in India, and you end up with thousands of tonnes of usage of concentrate, mostly imported from Germany, the US and China or produced by a few local manufacturers concentrated in the west and south of India.

Tier-2 and Tier-3 heavy states with the highest unmet demand are Uttar Pradesh, Bihar, West Bengal, Odisha, Jharkhand, Rajasthan, and Madhya Pradesh with dialysis infrastructure growing under PMNDP and local manufacturing is close to zero. The CDSCO classification of haemodialysis concentrate as a Class C medical device has created a slight regulatory moat: new players have to go through a process of manufacturing licence for the product, which disables fly by night operators but does not prevent serious MSME investors.

The supply situation for the cleaning chemicals – sodium hypochlorite solution, citric acid and acetic acid for disinfecting dialysis machines – is even more simple. Very few of these products are branded, and they are purchased from industry chemical suppliers as needed by dialysis centres, and may not be pure in quality. A manufacturer with the capacity to provide pharma-grade cleaning chemicals as well as dialysate concentrate to the same buyer is on a head-start in the procurement process.

Get Detailed Insights from This Book: Industrial Chemicals Technology Hand Book

TABLE 1: State-wise Demand Profile and Key Industrial Clusters for Hemodialysis Dialysate Concentrate

Source: IMARC Group India Dialysis Market Report; NHM Tamil Nadu NDP data; Pharmadocx Industry Analysis

Section 3: Why the Window Is Open Right Now

Three forces are all coming together at once. According to the government’s direction to Parliament, the Pradhan Mantri National Dialysis Programme has extended its reach to 751 districts, and is moving towards the taluka level. The opening of a new dialysis centre in a district represents a new customer base, one that will purchase concentrate at regular intervals and who is often more willing to pay any price for concentrate because they need it to keep their patients alive. Every new dialysis center in a district becomes a new customer for concentrate, one who cannot afford to not have it, and who often will pay any price for it because it helps keep their patients alive.

Secondly, the import dependency of India in the medical devices is a policy concern. The PLI scheme for Medical Devices provides an incentive of 5% for an incremental sale for manufacturer over 5 years period. The medical devices PLI framework applies to dialysate concentrate. It is administered by Ministry of Health and Family Welfare in collaboration with DPIIT and the list of approved applicants already includes dialysis consumables. If it is a new unit with a moderate capex, a 5% revenue top-up by the government makes a significant difference to the payback period.(Hemodialysis Dialysate Concentrate)

Third, demographics are driving the show. India has more than 10.1 crore diabetic population which is the largest diabetic population in the world. Another 22 crore adults suffer from hypertension. These both are a major cause of chronic kidney disease. With increasing recognition of kidney health and increased screening in Tier-2 cities, the number of new dialysis patients will continue to expand in the next ten years.

The entry conditions are relatively easy for an MSME manufacturer. Other relevant government schemes that are directly beneficial to this business are: PMEGP (Prime Minister’s Employment Generation Programme) which provides 15-35% capital subsidy on projects up to ₹50 lakh for manufacturing units through the kviconline.gov.in; and CGTMSE (Credit Guarantee Fund Trust for Micro and Small Enterprises) which permits collateral-free loans up to ₹2 crore through any scheduled bank for Udyam-registered units.

Get Detailed Project Report (DPR): Industrial Cleaning and Detergent Projects Guide

Step-by-Step Setup Guide

Step 1 — Assess your product mix and target market

First use two to three products: liquid acid concentrate (Part B — bicarbonate type), bicarbonate concentrate (Part B liquid), sodium hypochlorite cleaning solution. The technical, regulatory and demand barriers are minimal, low, and predictable, respectively, for these. Wait until manufacturing and QC systems are stable before adding the dry granulated powder concentrate (Part A).

Step 2 — Location and space

At least 1500 square feet for a small unit, 3000 square feet for a mid-scale facility. Opt for industrial areas in the chemical manufacturing clusters such as Ankleshwar or Vapi in Gujarat, Patancheru near Hyderabad, Ambernath in Maharashtra or SIDCO estates in Tamil Nadu. These are places with a stable utility supply system, close chemical raw material suppliers, and convenient transport to hospital.

Step 3 — Core machinery required

• SS 316L mixing and blending tanks (500 litre to 2,000 litre capacity)
• Reverse osmosis (RO) + deionised (DI) water purification system — critical, because the quality of water has impact on product safety
• Semi-automatic or automatic liquid filling and sealing line
• Powder granulation and blending equipment (for dry Part A concentrate)
• Quality control lab equipment: pH meter, conductivity analyser, osmometer, sterility testing setup
• The finished goods are temperature sensitive and require cold storage (bicarbonate solutions are included).

Stage 4 – Raw material procurement

Firstly, Key inputs are: sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium acetate or acetic acid, dextrose and sodium bicarbonate. Moreover, Domestically all are available. Furthermore, We source NaCl in bulk from the Saurashtra coast of Gujarat and the salt belt of Rajasthan. In addition, The pharmaceutical grade salts are available from the supplier in Hyderabad, Ahmedabad and Mumbai. Additionally, Chemical distributors across the country supply cleaning chemicals such as sodium hypochlorite and citric acid at commodity prices, and these chemicals are widely available throughout the country. (Hemodialysis Dialysate Concentrate)

Related Article: Specialty Chemicals Business in India: ₹1 Lakh Crore Opportunity, Investment & Profit Guide

Step 5 — Regulatory licences and approvals

• CDSCO MD-9 Manufacturing Licence — Mandatory for haemodialysis concentrate (Class C medical device under MDR 2017). Apply through the CDSCO online portal. Requires a test licence (MD-13) first, product testing at CDSCO-approved lab, site audit, and final approval. Timeline: 6–12 months.
• State Labour Department — Factory Licence, under “Factories Act”, 1948.
• Pollution NOC / Consent to Establish – From State Pollution Control Board. Probably green/Orange.
• Registration under GST — Before making sales to the public.
• Udyam Registration — MSME Registration at udyamregistration.gov.in to avail all Government Schemes.
• BIS IS: 13450 — The Indian Standard for haemodialysis concentrates. Compliance is expected by hospital procurement departments even were not legally mandatory.

Step 6 — Team and timeline

An MIV (Minimum Viable Team): 1 production supervisor (diploma in pharmacy/chemistry), 2 production operators, 1 QC analyst and 1 sales/distribution executive. The founders and owners often do the procurement and sales themselves for the first three months. It takes 10-14 months for the complete CDSCO approval process from registration to first production. Plan for 18-months from decision to break even.

TABLE 2: Investment Breakdown — Small vs Mid-Scale Hemodialysis Dialysate Concentrate Unit

Source: NIIR Project Consultancy Services techno-economic estimates; MSME Ministry capex benchmarks

Financial Snapshot

Capital expenditure – ₹40–65 lakh for small unit (1,500 sq ft, 2–3 products) and ₹95 lakh–₹1.5 crore for mid-scale unit with complete range of products.

Opex per month: The small unit has operating cost of Rs. 6-8 lakh/month (including raw material – 55% of opex, utilities, labour – 4-5 staff, packaging and consumables).

Revenue at 60% capacity: ₹9-lakh-to ₹12-lakh per month for a small unit. At full capacity: ₹15–20 lakh/month. The realisation being above and below depends on the customer mix, with the PMNDP government tenders commanding realisations between ₹35 and 50 per litre of liquid concentrates compared to ₹60 and 90 per litre of the private hospital chains.

Gross margin: 38-46% on liquid concentrates and slightly lower (higher energy and labour cost) on dry powder. Net margin (on full capacity basis): 18–24%, if they are able to find their raw materials efficiently; and if they are not buying them through distributors but through hospitals directly.

Payback period: 28-36 months at 70% and above capacity utilisation, for a small unit. Units that use cleaning chemicals with the same customers that use the dialysate can expect a faster payback (22-28 months) because revenue per sales call is higher.

 TABLE 3: Applicable Government Schemes, Eligibility, and Benefit

Source: MSME Ministry; DPIIT PLI Scheme; KVIC PMEGP portal; SIDBI CGTMSE guidelines

Choose the right startup backed by real market demand

Getting Expert Guidance Before You Invest

Firstly, Founders should have a detailed techno-economic feasibility study before investing capex in a regulated medical device category such as haemodialysis concentrate. Moreover, Niir Project Consultancy Services (NPCS) at niir.org specializes in such pre-investment analysis including plant layout design, selection of machinery, raw material cost modelling, roadmap for compliance with regulatory requirements and financial projections tailored to the Indian market. Furthermore, NPCS has already released detailed project reports on haemodialysis dialysate concentrate manufacturing, including formulation notes, equipment sourcing guide and revenue models based on the capacity. Additionally, Their reports can be found on entrepreneurindia.co and represent a solid foundation to get founders from the idea stage to an investable proposition without employing a full-service consultant up front. Thus, A project report worth ₹10,000 to ₹25,000 is worth the investment for an investment amount of ₹50 lakh – ₹1.5 crore.

One Decision. One Next Step.

No one would want to paint the dialysate concentrate business as a sexy venture. There is no viral moment, there is no consumer brand to build, there’s no VC interest in. What is there: a consistent, non-discretionary demand from a patient population that continues to increase, a government programme actively creating a larger buyer group and a supply chain with great geographic gaps to be filled.(Hemodialysis Dialysate Concentrate)

That’s a seriously under explored manufacturing play if you are an industrial investor or are a first-generation entrepreneur with access to ₹50-60 lakh of seed money and have a chemistry/Pharma background. The regulatory route is in place. It’s the institutions who are the buyers and not wild consumers. Once you pass the test and make the hospital’s approved vendor list, the money is in contract.

Now, proceed to commission a techno-economic feasibility study (TES) (NPCS, niir.org) and at the same time launch your CDSCO pre-application engagement. These can occur simultaneously. The one mistake that first-time manufacturers of medical devices make in India is waiting for one to finish before taking up the other.

ENTREPRENEUR SPOTLIGHT

A Hyderabad-Based Pharma Distributor Who Moved Upstream

Firstly, A mid-career pharma distributor based in Hyderabad identified the perennial shortage of concentrate as he made routine stops at various dialysis centres spread across the Tier 2 districts of Telangana. Additionally, With 12 years of distribution experience and hospital purchasing managers for contacts, he raised an MSME loan at CGTMSE support and under the PMEGP capital subsidy and established a 2,500 sq ft concentrate manufacturing facility on the outskirts of Patancheru. Consequently, Within 30 months the unit was providing concentrate to 18 dialysis centers in Telangana and AP with monthly turnover peaking at 14 lakhs. The lesson: “Obtain your CDSCO approval before buying machinery, not after,” emphasizes him. Ultimately, The constraint on time for regulatory approval and not capital, it turns out, is the critical one.(Hemodialysis Dialysate Concentrate

Frequently Asked Questions

Q1: What is the minimum investment to setup a hemodialysis dialysate concentrates manufacturing unit in India?

The total capital expenditure required for machinery, water purification and QC lab along with working capital and pre-operative expenses in order to establish a small-scale unit for producing two to three liquid concentrates should be in the range of 40-65 lakh. For full range of product which include dry granulated powder and cleaning chemicals, medium scale unit will be established for around 95 lakh to 1.5crore.

Q2: What are the necessary regulatory licenses before starting a manufacturing operation?

Most essential License for hemodialysis dialysate concentrate (Class C medical device as per the Medical Devices Rules 2017) is CDSCO MD-9 Manufacturing Licence. In addition, you would require a Factory License, Pollution NOC from State Pollution Control Board, GST registration, and Udyam Registration as an MSME.

Q3: Where can I source raw materials in India?

Bulk chemical manufacturers in Hyderabad, Ahmedabad, and Mumbai supply pharma-grade salts such as NaCl, KCl, CaCl₂, MgCl₂, NaHCO₃, and sodium acetate. For cleaning chemicals, we should source industrial-grade sodium hypochlorite and citric acid as commodity products from regional chemical distributors. Always ensure that suppliers have GMP certification and provide a Certificate of Analysis (COA) to meet CDSCO audit requirements.

Q4: Is it a profitable venture and what would be my margins?

With proper management and optimal utilization of installed capacity, the unit can achieve net profit margins of 18–24%, especially when targeting private hospitals and dialysis centers. Tender sales (under PMNDP) will have relatively low net margins of 8-12% but they provide more stable revenue flows and assured payments. A combination of both private and tender sales will give the desired cash flows and net margins.

Q5: What are the schemes providing financial support for such a venture?

A: The PMEGP Scheme (15-35% capital subsidy through kviconline.gov.in), CGTMSE (collateral-free loans up to 2 crore), PLI Scheme for Medical Devices (5% incentive on incremental sales), state industrial promotion policies offering subsidies for land and power are the main ones. A prerequisite for applying for all the aforementioned schemes is the Udyam registration of the unit.

Q6: Where can I find a detailed project report for this venture?

A: NIIR Project Consultancy Services (niir.org) provides a comprehensive project report for manufacturing hemodialysis dialysate concentrate that includes the details on product formulation, machinery list, raw material cost tables, financial projections and all necessary regulatory compliance guidelines. These reports can be purchased as individual documents. Entrepreneurindia.co also provides detailed project reports for similar ventures.